GB2512558A - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents

Pluripotent germ layer origin antigen presenting cancer vaccine Download PDF

Info

Publication number
GB2512558A
GB2512558A GB1414403.4A GB201414403A GB2512558A GB 2512558 A GB2512558 A GB 2512558A GB 201414403 A GB201414403 A GB 201414403A GB 2512558 A GB2512558 A GB 2512558A
Authority
GB
United Kingdom
Prior art keywords
antigen presenting
cancer vaccine
germ layer
pluripotent germ
presenting cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1414403.4A
Other languages
English (en)
Other versions
GB201414403D0 (en
Inventor
Andrew Cornforth
Robert Dillman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoStem Oncology LLC
Original Assignee
California Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cells Inc filed Critical California Stem Cells Inc
Publication of GB201414403D0 publication Critical patent/GB201414403D0/en
Publication of GB2512558A publication Critical patent/GB2512558A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
GB1414403.4A 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine Withdrawn GB2512558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (2)

Publication Number Publication Date
GB201414403D0 GB201414403D0 (en) 2014-10-01
GB2512558A true GB2512558A (en) 2014-10-01

Family

ID=48905824

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1414403.4A Withdrawn GB2512558A (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Country Status (13)

Country Link
US (1) US20150064217A1 (cg-RX-API-DMAC7.html)
EP (1) EP2809775B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015506698A (cg-RX-API-DMAC7.html)
KR (1) KR20140143361A (cg-RX-API-DMAC7.html)
CN (1) CN104540937A (cg-RX-API-DMAC7.html)
AU (1) AU2013215116A1 (cg-RX-API-DMAC7.html)
CA (1) CA2863653A1 (cg-RX-API-DMAC7.html)
GB (1) GB2512558A (cg-RX-API-DMAC7.html)
HK (2) HK1209455A1 (cg-RX-API-DMAC7.html)
IL (1) IL233928A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ628292A (cg-RX-API-DMAC7.html)
SG (1) SG11201404543UA (cg-RX-API-DMAC7.html)
WO (2) WO2013116541A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
WO2016056596A1 (ja) 2014-10-07 2016-04-14 日本電気株式会社 Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
US11291718B2 (en) * 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
JPWO2018131659A1 (ja) * 2017-01-11 2019-12-12 国立研究開発法人国立がん研究センター 免疫療法剤
IL268744B2 (en) * 2017-02-17 2024-08-01 Aivita Biomedical Inc Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053176A2 (en) * 2001-01-08 2002-07-11 Hadasit Medical Research Services And Development Ltd. An autologous anti-cancer vaccine
US20080311142A1 (en) * 2006-09-28 2008-12-18 Yu John S Cancer vaccines and vaccination methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0212545B8 (pt) * 2001-09-06 2021-05-25 Northwest Biotherapeutics Inc método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
CN101052709B (zh) * 2004-10-25 2012-06-27 贝勒研究院 装载热激黑素瘤细胞体的树突细胞
KR101374091B1 (ko) * 2005-07-29 2014-03-17 프로비던스 헬스 앤드 서비시즈, 오레곤 수포에 담긴 불완전 리보솜 생성물(DRibble) 및 면역 반응을 자극하기 위해 이를 이용하는 방법
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053176A2 (en) * 2001-01-08 2002-07-11 Hadasit Medical Research Services And Development Ltd. An autologous anti-cancer vaccine
US20080311142A1 (en) * 2006-09-28 2008-12-18 Yu John S Cancer vaccines and vaccination methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOGANNATH, CHINNASWAMY ET AL 'Autophagy enhances the efficacy of BCGvaccine by increasing peptidepresentation in mouse dendritic cells', NatureMedicine, 01 March 2009, Vol.15, No.3,pp.267-276.See abstract;pages 267,268 and 273. *
LI, YUHUAN ET AL. 'Efficient cross-presentation depends on autophagy in tumor cells',Cancer Research, 01 September 2008, Vol.68, No.17,,pp.6889-6895. *
MITO. KAI ET AL 'IFN markedly cooperates with intratumoral dendritic cellvaccine in dog tumor models' Cancer Research, 07 September 2010, Vol 70, No.18,pp.7093-7101.See abstract;pages 7093, 7094, 7096 and 7100; fig 1. *
YAP, GEORGE ET AL 'Autophagic elimination of intracellular parasi tes",Autophagy,05 March 2007, Vol.3, No.2,pp.163-165.See abstract;pages 163 and 164; fig 1. *

Also Published As

Publication number Publication date
KR20140143361A (ko) 2014-12-16
US20150064217A1 (en) 2015-03-05
GB201414403D0 (en) 2014-10-01
EP2809775A1 (en) 2014-12-10
HK1209455A1 (en) 2016-04-01
SG11201404543UA (en) 2014-08-28
EP2809775A4 (en) 2015-07-01
HK1202432A1 (en) 2015-10-02
JP2015506698A (ja) 2015-03-05
WO2013116505A1 (en) 2013-08-08
CN104540937A (zh) 2015-04-22
WO2013116541A1 (en) 2013-08-08
IL233928A0 (en) 2014-09-30
CA2863653A1 (en) 2013-08-08
AU2013215116A1 (en) 2014-08-21
NZ628292A (en) 2016-09-30
EP2809775B1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2024010239A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
MY199874A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MX385933B (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
EP4643874A3 (en) Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
PH12016501384B1 (en) Human antibodies to pd-l1
EP4245376A3 (en) Antibody molecules to pd-l1 and uses thereof
TN2015000050A1 (en) Methods of treating a tauopathy
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
UY35063A (es) Composiciones y métodos que se dirigen a células estromales para el tratamiento del cáncer
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
BR112016024957A2 (pt) métodos aperfeiçoados para fabricação de terapias celulares adotivas
WO2013126733A8 (en) Use of icos-based cars to enhance antitumor activity and car persistence
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX2014004326A (es) Anticuerpos a cd1d.
WO2015197874A3 (en) Combination of cd95/cd95l inhibition and cancer immunotherapy
HK1202432A1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
HK1201176A1 (en) Antigen presenting cancer vaccine

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20141002 AND 20141008

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202432

Country of ref document: HK

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20180308 AND 20180314

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1202432

Country of ref document: HK